Alpha Cognition (NASDAQ:ACOG) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Alpha Cognition (NASDAQ:ACOG) in a research note released on Monday morning,Benzinga reports. HC Wainwright currently has a $20.00 price objective on the stock.

Separately, Raymond James upgraded shares of Alpha Cognition to a “moderate buy” rating in a report on Tuesday, March 25th.

Alpha Cognition Trading Down 8.5 %

Alpha Cognition stock opened at $5.06 on Monday. The stock has a market capitalization of $81.06 million, a price-to-earnings ratio of -1.98 and a beta of 2.50. Alpha Cognition has a 1-year low of $4.66 and a 1-year high of $7.00. The business’s 50-day moving average price is $5.83.

Alpha Cognition (NASDAQ:ACOG) last posted its earnings results on Wednesday, April 2nd. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.03).

Hedge Funds Weigh In On Alpha Cognition

A number of institutional investors have recently added to or reduced their stakes in ACOG. National Bank of Canada FI purchased a new stake in Alpha Cognition in the fourth quarter worth about $69,000. Manatuck Hill Partners LLC bought a new stake in shares of Alpha Cognition in the 4th quarter worth approximately $395,000. Tudor Investment Corp ET AL bought a new stake in shares of Alpha Cognition in the 4th quarter worth approximately $412,000. MYDA Advisors LLC bought a new position in Alpha Cognition during the 4th quarter valued at approximately $589,000. Finally, Bleichroeder LP purchased a new position in Alpha Cognition during the fourth quarter valued at $1,024,000.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.